दवाएँ
श्रेणियाँ
Featured
4,000+ दवा प्रोफ़ाइल
आणविक डेटा, क्रियाविधि और नैदानिक औषध विज्ञान।
Guide Series
अन्वेषण करें
Reference Content
तुलनाएँ
दवाओं का प्रत्यक्ष तुलनात्मक विश्लेषण
दवाओं की यात्राएँ
ADME विवरण
दवा परिवार
SAR संरचनात्मक संबंध
वे महत्वपूर्ण क्षण जिन्होंने आधुनिक औषध विज्ञान को आकार दिया — खोजें, सफलताएँ और सीखे गए पाठ।
Morphine's isolation established the field of alkaloid chemistry and proved that pure chemical compounds underlie the activity of crude plant drugs. This principle—that pharmacologically active …
Aspirin exemplifies the pharmaceutical optimisation of a natural product: chemical modification converted an effective but irritating compound into a tolerated drug. It also illustrates how …
Receptor theory transformed pharmacology from a descriptive to a mechanistic science. The concept that drugs act by binding to specific molecular targets—and that [[term:selectivity|selectivity]] for …
Penicillin's discovery and development created the antibiotic era, reducing mortality from bacterial infections that had been uniformly fatal. It also established the natural product screening …
The Sulfanilamide Disaster directly created the modern drug safety regulatory framework. The Federal Food, Drug, and Cosmetic Act of 1938 established the pre-market safety approval …
Industrial penicillin production established the fermentation technology and pharmaceutical manufacturing infrastructure that underpins the production of antibiotics, vitamins, amino acids, and eventually recombinant biologics. It …
Streptomycin provided the first effective treatment for tuberculosis, one of history's deadliest infectious diseases. The 1948 MRC streptomycin trial established the randomised controlled trial as …
Ahlquist's receptor classification provided the theoretical basis for selective adrenergic drugs— beta-blockers, alpha-blockers, and selective beta-agonists for asthma. It demonstrated that receptor subtype [[term:selectivity|selectivity]] could …
Chlorpromazine founded biological psychiatry and created the field of psychopharmacology. It demonstrated that severe psychiatric illness had a biological substrate amenable to pharmacological intervention, shifted …
Imipramine established depression as a biologically treatable illness and founded the tricyclic antidepressant class. Its mechanism underpinned the monoamine hypothesis of depression, which— despite its …
Thalidomide's teratogenic catastrophe revealed that drugs can have completely different toxicological profiles across species and developmental stages, revolutionised preclinical reproductive toxicology requirements, and established that …
The Kefauver-Harris Amendment established [[term:efficacy|efficacy]] as a regulatory requirement alongside safety, making the randomised controlled trial central to drug approval globally. Its framework—pre-clinical testing, IND …
Propranolol validated receptor-targeted drug design as a strategy—demonstrating that systematic application of receptor pharmacology to a defined clinical need could produce a world-changing drug. The …
Vane's discovery of aspirin's mechanism founded modern eicosanoid pharmacology and established prostaglandins as key mediators of inflammation, pain, and fever. It led directly to the …
Hybridoma technology made it possible to produce unlimited quantities of a precisely defined antibody, transforming diagnostics and creating the largest and fastest-growing class of biopharmaceuticals. …
Cimetidine was the first drug deliberately designed by rational receptor-pharmacology methodology to achieve commercial and clinical success, validating Black's approach and demonstrating that rational drug …
Captopril was the first drug designed using the structure of a target enzyme's active site— inaugurating structure-based drug design as a practical drug discovery strategy. …
Recombinant insulin proved that genetic engineering could produce therapeutic human proteins at commercial scale with acceptable safety—founding the biotechnology pharmaceutical industry. Its approval established the …
Muromonab-CD3's approval opened the regulatory pathway and established clinical proof-of-concept for all subsequent therapeutic monoclonal antibodies. Its limitations—murine immunogenicity and cytokine release syndrome—directly drove the …
AZT demonstrated that HIV replication could be pharmacologically inhibited, transforming AIDS from a uniformly fatal illness into a treatable condition—though full therapeutic transformation awaited combination …
Lovastatin inaugurated the statin era, which produced the most robust cardiovascular mortality reduction data of any drug class. Statins demonstrated that sustained LDL lowering translates …
Fluoxetine demonstrated that SERT [[term:selectivity|selectivity]] could produce antidepressant [[term:efficacy|efficacy]] with a safety and tolerability profile that made treatment of depression practical for primary care physicians. …
Omeprazole established proton pump inhibition as the dominant strategy for acid suppression, achieving more profound and sustained gastric acid reduction than H2 antagonists and enabling …
Saquinavir validated structure-based drug design against a viral enzyme and provided the first [[term:protease-inhibitor|protease inhibitor]] building block for HAART, which transformed HIV/AIDS from a death …
Rituximab was the first approved anti-cancer [[term:monoclonal-antibody|monoclonal antibody]], proving that Ehrlich's magic bullet concept was clinically achievable. It established CD20 as a validated oncology target, …
Sildenafil illustrated that rigorous attention to unexpected clinical signals during trials can salvage—and dramatically redirect—a failing programme. It created the PDE5 inhibitor drug class, established …
Trastuzumab demonstrated that an oncogenic driver gene—present in a defined patient subset— could be pharmacologically silenced with a [[term:monoclonal-antibody|monoclonal antibody]], dramatically improving outcomes in a …
Imatinib proved the concept that a single oncogenic kinase can be pharmacologically silenced by a small molecule, converting a lethal leukaemia into a manageable chronic …
Completing the human genome reference sequence provided the foundational resource for all subsequent genomic medicine: GWAS, [[term:pharmacogenomics|pharmacogenomics]], rare-disease gene discovery, and cancer genomics. It catalysed …
The rofecoxib withdrawal reshaped [[term:pharmacovigilance|pharmacovigilance]] globally, prompting mandatory post-marketing commitments, expanded use of FDA's Sentinel System for real-world safety monitoring, and more stringent cardiovascular risk …
Bevacizumab validated Judah Folkman's angiogenesis hypothesis after three decades of controversy and launched the anti-VEGF drug class. It established tumour vasculature as a legitimate therapeutic …
Gardasil established that a vaccine could prevent a human malignancy by eliminating the causative infectious agent. It validated the VLP platform as safe and highly …
Ipilimumab proved that releasing immunological brakes could produce durable tumour regression and long-term survival in a cancer previously resistant to all systemic therapy. It established …
Sofosbuvir made chronic hepatitis C—a major global cause of cirrhosis and hepatocellular carcinoma affecting 70 million people—curable with a short oral course in virtually all …
The 2013 CAR-T results demonstrated that genetically engineered autologous immune cells could achieve deep and durable complete remissions in patients with haematological malignancies refractory to …
PD-1 blockade extended checkpoint immunotherapy to a much broader range of tumour types than CTLA-4 inhibition, demonstrating that blocking immunosuppressive signals within the tumour microenvironment …
The 2015 debates crystallised [[term:crispr-drug-discovery|CRISPR]]-Cas9 as both the most powerful genome-editing tool yet available and the focal point of the most consequential bioethical deliberation in …
Kymriah's approval established [[term:car-t-cell-therapy|CAR-T cell therapy]] as a commercial medical product, creating the first approved gene therapy for cancer and demonstrating that a personalised, patient-derived …
Luxturna proved that an AAV vector could deliver a functional gene in vivo and restore meaningful physiological function in a human genetic disease, validating in …
Patisiran validated RNAi as a therapeutic mechanism and lipid nanoparticle as a clinical delivery vehicle, establishing RNA-based therapeutics as a viable pharmacological class. It demonstrated …
mRNA COVID-19 vaccines demonstrated that a nucleic acid platform could be designed, scaled, and authorised at population scale in under one year, achieving [[term:efficacy|efficacy]] rates …
Aducanumab's approval and subsequent withdrawal crystallised the debate over whether amyloid plaque reduction constitutes a valid [[term:surrogate-endpoint|surrogate endpoint]] for Alzheimer's clinical benefit, ultimately strengthening the …
AlphaFold2 solved the protein structure prediction problem at proteome scale, providing free high-accuracy structural models for virtually every known protein. This transformed structure- based drug …
Evusheld demonstrated that long-acting [[term:monoclonal-antibody|monoclonal antibody]] combinations with Fc-extended [[term:half-life|half-life]] could provide months of prophylactic protection against respiratory viral infection, establishing a template for passive …
Semaglutide at 2.4 mg demonstrated that pharmacological appetite regulation could achieve clinically meaningful weight reduction approaching surgical outcomes, repositioning obesity from a lifestyle issue to …
Casgevy's approval realised the clinical potential of [[term:crispr-drug-discovery|CRISPR]]-Cas9 gene editing in human patients, demonstrating durable functional cure of two severe inherited haemoglobin disorders through a …
Lecanemab became the first Alzheimer's therapy to demonstrate both amyloid [[term:clearance|clearance]] and statistically significant slowing of clinical decline in a prospectively designed Phase III trial …
The multi-indication expansion of GLP-1 agonists revealed a mechanistic pleiotropy—metabolic, anti-inflammatory, cardiovascular, renal, and neurological—that fundamentally repositioned the drug class from diabetes management to broad …
The first [[term:protac|PROTAC]] to enter Phase III trials represented the clinical validation of targeted protein degradation as a therapeutic modality distinct from enzymatic inhibition, expanding …
The advance of AI-generated drug candidates into Phase II trials demonstrated that artificial intelligence can meaningfully compress the drug discovery timeline—from years to months—by integrating …